Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. Borsetto D, Polesel J, Tirelli G, Menegaldo A, et al. Laryngoscope 2020 Jun 26. doi: 10.1002/lary.28882.

Read + Share

Amedeo Smart

Independent Medical Education

Borsetto D, Polesel J, Tirelli G, Menegaldo A, et al. Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. Laryngoscope 2020 Jun 26. doi: 10.1002/lary.28882.
PMID: 32589769